FDA approves Bemotrizinol: New OTC sunscreen broad‑spectrum UV filter cleared for U.S. use
The FDA has added bemotrizinol to the OTC sunscreen monograph as a GRASE broad‑spectrum UV filter, allowing up to 6% use and paving the way for U.S. launches (first: Parsol Shield) expected nationwide around mid‑2026.
- Regulatory action: The FDA issued a final order adding bemotrizinol to the OTC sunscreen monograph.
- Use & limits: Bemotrizinol is permitted up to 6% and is approved for people aged 6 months and older (FDA).
- Market rollout: DSM‑Firmenich plans to launch Parsol Shield first, with an 18‑month exclusivity; broader availability expected after mid‑2026 (CBS, video briefing).
What the FDA did
On Tuesday the FDA issued a final administrative order that adds bemotrizinol to the list of allowed OTC sunscreen active ingredients. The move follows a proposed order published Dec. 12, 2025, which was open for public comment (FDA).
This is the first new sunscreen active added under the streamlined monograph order process created by the CARES Act, replacing slower rulemaking with an order pathway designed to speed decisions for safe, effective OTC drugs (FDA).
“We’re continuing to modernize the regulation of sunscreen and other over‑the‑counter drug products,” said FDA Commissioner Marty Makary, MD, MPH. “Americans deserve timely access to the best safe, effective and consumer‑friendly over‑the‑counter products available.” (FDA)
Why this matters now
U.S. sunscreens historically relied on older filters while many newer, high‑performance filters used in Europe and Asia remained unavailable here because of regulatory delays. Bemotrizinol (also called BEMT or Tinosorb S) has been widely used overseas and offers broad protection against both UVA and UVB, narrowing the gap between U.S. products and those sold in Europe and parts of Asia (Time, CBS).
How bemotrizinol works
Bemotrizinol is a synthetic organic UV filter that absorbs a wide range of ultraviolet wavelengths. Its broad‑spectrum action protects against UVB (sunburn) and UVA (skin aging and cancer risk). The filter is photostable, so it breaks down less in sunlight than some older chemicals, allowing formulators to achieve high performance with fewer total filters (FDA; Time).
Safety and absorption
The FDA concluded bemotrizinol is generally recognized as safe and effective (GRASE) for people ages 6 months and up. That finding was based on data for skin absorption, systemic exposure, irritation, sensitization and toxicology. Officials reported low skin absorption and rare irritation, noting the ingredient’s relatively large molecular size may limit systemic exposure — a key concern in recent sunscreen reviews (FDA; CBS).
Product rollout and exclusivity
DSM‑Firmenich requested the monograph order and plans to market bemotrizinol under the trade name Parsol Shield in the U.S. The company expects a mid‑2026 launch; exact timing, formulation and labeling will determine final claims. Under the FDA order, DSM receives an 18‑month exclusivity, after which other brands may use bemotrizinol up to 6% following monograph rules (FDA; video briefing).
Regulatory context: CARES Act and sunscreen reform
Bemotrizinol’s approval is the first under the OTC monograph order process established by the CARES Act. That change aims to make reviews faster and more predictable. Recent “Safe Sunscreen” reform efforts also encouraged the FDA to address long‑pending sunscreen ingredients more efficiently; the agency has said it welcomes additional monograph order requests for other actives (FDA).
What consumers and makers should expect
For shoppers: Usage is the same as other OTC sunscreens — apply generously, reapply at least every two hours, and pair sunscreen with hats, long sleeves and shade for extended outdoor exposure. Labels will list “bemotrizinol” in the active ingredients panel and may show the trade name Parsol Shield. Some users may notice lighter textures because formulators can use fewer filters (FDA guidance; Time).
For manufacturers: DSM’s 18‑month exclusivity gives a short head start to bring Parsol Shield to market. After exclusivity ends, other companies may add bemotrizinol to formulas, likely increasing competition and availability. The FDA has signaled it will process future requests more quickly, potentially opening doors to more modern sunscreen actives (FDA).
Perspectives from regulators and experts
Karen Murry, MD, acting director of the FDA’s Office of Nonprescription Drugs, called bemotrizinol “a welcome addition to the current array of effective sunscreen active ingredients already available to American consumers,” and said the agency looks forward to working with other companies on new active ingredients (FDA).
Cosmetic chemists and market experts note bemotrizinol’s broad coverage and stability make it a useful tool for formulators — enabling high SPF with lighter, more comfortable textures that may improve consistent use among people who avoid greasy sunscreens (Time).
Implications for the United States
Economic impact
- Retail & manufacturing: Parsol Shield’s launch could boost DSM sales and, later, sales for other brands that adopt bemotrizinol; retailers may see seasonal demand increases (FDA).
- Pricing & competition: The 18‑month exclusivity may keep initial prices higher; competition after exclusivity could reduce costs and expand choices (video briefing).
Political consequences
- Regulation & reform: The decision underscores CARES Act changes and may lessen criticism that the FDA was too slow on sunscreen modernization (FDA).
- Local officials: Health departments may update sun‑safety guidance and partner with retailers for outreach to outdoor workers and schools.
Social effects
- Outdoor workers & rural families: More comfortable, high‑performing sunscreens could increase regular use among farmers, ranchers and construction crews, reducing sunburn risk (FDA guidance).
- Children & schools: Approval for ages 6 months and up may affect daycare and youth sports sunscreen policies (FDA).
Cultural relevance
Practical communities that value proven, straightforward tools may find reassurance in the FDA’s explicit safety finding and bemotrizinol’s European track record. Clear labeling and simple claims will be important for shoppers who favor trusted local retailers.
Practical applications for daily life
- Look for bemotrizinol or Parsol Shield on labels once products arrive; use them as you would other sunscreens: apply liberally and reapply every two hours.
- Those who disliked greasy sunscreens may find new bemotrizinol formulas more comfortable and easier to keep on during long outdoor work or recreation (Time).
